IMVT-1402’s open-label Phase 1 trial in difficult-to-treat rheumatoid arthritis enrolled 170 patients, with 165 evaluable participants achieving Week 16 response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70, and no new safety signals were identified. Brepocitinib received Breakthrough Therapy designation for cutaneous sarcoidosis, initiated a registrational trial in lichen planopilaris in March 2026 and is on track for a dermatomyositis commercial launch by September 2026.

Roivant, Genevant and Arbutus finalized a $2.25 billion global settlement with Moderna to resolve all U.S. and international patent-infringement litigation. Moderna will pay $950 million in July 2026 and an additional $1.3 billion contingent upon resolution of its Section 1498 appeal.

Roivant reported consolidated cash, cash equivalents and marketable securities of $4.3 billion as of March 31, 2026, supporting a runway into profitability. The company expects topline data for IMVT-1402 in D2T RA, Phase 3 results for brepocitinib in non-infectious uveitis and cutaneous lupus, and mosliciguat PHocus study readouts in the second half of 2026.